Immunomedics Inc. announced Tuesday that its lung cancerimaging agent ImmuRAID-CEA showed clinical benefit in 33percent of 54 cases in a multicenter Phase II clinical trial.Moreover, the company's (NASDAQ:IMMU) imaging agentaccurately diagnosed at least one lesion in 90 percent of trialpatients with known disease.

Immunomedics' vice president for medical affairs, Carl Pinsky,presented these results at the Bear Stearns Sixth Annual HealthCare Conference in New York. Pinsky said the Morris Plains,N.J., company now intends to take ImmuRAID-CEA into PhaseIII trials for imaging lung cancer, in conjunction with its NorthAmerican partner Adria Laboratories of Columbus, Ohio.

ImmuRAID-CEA consists of an antibody fragment labeled withthe radioisotope technitium-99m that attaches to the tumormarker CEA (carcinoembryonic antigen). The product iscurrently under review for marketing approval by regulatoryagencies in the U.S., Canada and Europe as an imaging agent forcolorectal cancer.

(c) 1997 American Health Consultants. All rights reserved.